Abstract
Hemophilia A is a rare bleeding disorder resulting from a lack of functional factor VIII (FVIII). Therapy consists of replacement with exogenous FVIII, but is complicated by high inter-patient variability. A population pharmacokinetics (PopPK) approach can facilitate the uptake of an individualized approach to hemophilia therapy. We developed a PopPK model using data from seven brands of standard half-life FVIII products. The final model consists of a 2-compartment structure, with a proportional residual error model and between-subject variability on clearance and central volume. Fat-free mass, age, and brand were found to significantly affect pharmacokinetic (PK) parameters. Internal and external evaluations found that the model is fit for Bayesian forecasting and capable of predicting PK for brands not included in the modelling dataset, and useful for determining individualized prophylaxis regimens for hemophilia A patients.
Similar content being viewed by others
References
Stonebraker JS, Bolton-Maggs PHB, MichaelSoucie J, Walker I, Brooker M (2010) A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 16(1):20–32
Ahlberg Å (1965) Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 36(sup77):3–132
Collins PW et al (2009) Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 7:413–420
Oldenburg J (2011) Prophylaxis in bleeding disorders. Thromb Res 127:S14–S17
Berntorp E, Spotts G, Patrone L, Ewenstein B (2014) Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biol Targets Ther 8:115
Fischer K, Collins PW, Ozelo MC, Srivastava A, Young G, Blanchette VS (2016) When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. J Thromb Haemost 14(5):1105–1109
Björkman S, Folkesson A, Jönsson S (2009) Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years. Eur J Clin Pharmacol 65(10):989–998
McEneny-King A, Iorio A, Foster G, Edginton AN (2016) The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. Expert Opin Drug Metab Toxicol 12(11):1313–1321
Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E (2017) Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. J Thrombs Haemost 15(12):2461–2465
Iorio A et al (2018) Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: rationale and general considerations. Res Pract Thromb Haemost 2(3):535–548
Samor B, Michalski C, Brandin M-P, Andre M-H, Chtourou S, Tellier Z (2012) A qualitative and quantitative analysis of von Willebrand factor contained in a very high-purity plasma-derived FVIII concentrate. Vox Sang 103(1):35–41
Morfini M, Marchesini E, Paladino E, Santoro C, Zanon E, Iorio A (2015) Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study. Haemophilia 21(2):204–209
Cafuir LA, Kempton CL (2017) Current and emerging factor VIII replacement products for hemophilia A. Ther Adv Hematol 8(10):303–313
Di Paola J et al (2007) ReFacto®1and Advate®2: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia 13(2):124–130
Recht M et al (2009) Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor V. Haemophilia 15(4):869–880
Kessler CM et al (2005) B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. Haemophilia 11(2):84–91
Gruppo RA, Brown D, Wilkes MM, Navickis RJ (2003) Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis–a meta-analysis. Haemophilia 9(3):251–260
Johnston A (2012) The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII? Ther Drug Monit 34(1):110–117
Pipe SW (2009) Functional roles of the factor VIII B domain. Haemophilia 15(6):1187–1196
Abrantes J, Nielsen E, Korth-Bradley J, Harnisch L, Jönsson S (2017) Elucidation of factor VIII activity pharmacokinetics: a pooled population analysis in patients with hemophilia a treated with moroctocog alfa. Clin Pharmacol Ther 102(6):977–988
Björkman S (2012) Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics To Age and Body Weight. Blood 119(2):612–618
Nestorov I, Neelakantan S, Ludden TM, Li S, Jiang H, Rogge M (2015) Population pharmacokinetics of recombinant factor VIII Fc fusion protein. Clin Pharmacol Drug Dev 4(3):163–174
Garmann D, McLeay S, Shah A, Vis P, MaasEnriquez M, Ploeger BA (2017) Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned—importance of including samples with factor VIII levels below the quantitation limit. Haemophilia 23(4):528–537
Jiménez-Yuste V et al (2015) The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A. J Thromb Haemost 13(3):370–379
Bolon-Larger M, Bressolle F, Chevalier Y, Chamouard V, Gomeni R, Boulieu R (2015) Population pharmacokinetics of continuous infusion of factor VIII in hemophilia-a patients undergoing orthopedic surgery. IJPPS 7(2):109–114
Karafoulidou A et al (2009) Population pharmacokinetics of recombinant factor VIII: C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients. Eur J Clin Pharmacol 65(11):1121–1130
Hazendonk H et al (2016) A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica 101(10):1159–1169
Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5):481–504
Al-Sallami HS, Goulding A, Grant A, Taylor R, Holford N, Duffull SB (2015) Prediction of fat-free mass in children. Clin Pharmacokinet 54(11):1169–1178
Brekkan A, Berntorp E, Jensen K, Nielsen EI, Jönsson S (2016) Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization. J Thromb Haemost 14(4):724–732
Konkle B (2014) von Willebrand factor and aging. Semin Thromb Hemost 40(06):640–644
Lenting PJ, Van Schooten CJM, Denis CV (2007) Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 4(7):1353–1360
Lalezari S et al (2014) Correlation between endogenous VWF: Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia 20(1):e15–e22
Turecek PL et al (2016) A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII: C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia 22(6):957–965
Barrowcliffe TW (2003) Standardization of FVIII & FIX assays. Haemophilia 9(4):397–402
Sommer JM et al (2014) Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia 20(2):294–300
Viuff D, Barrowcliffe TW, Saugstrup T, Ezban M, Lillicrap D (2011) International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 17(4):695–702
Chelle P et al (2014) Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. J Pharmacokinet Pharmacodyn. https://doi.org/10.1007/s10928-019-09637-4
Acknowledgements
We would like to thank the centres in the WAPPS-Hemo network for contributing data used for the external validation of the presented model. The full list of centres is found in Appendix.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Appendix: List of WAPPS-Hemo centres
Appendix: List of WAPPS-Hemo centres
Alberta Children’s Hospital, Calgary, Canada |
Amrita Hospital, Kochi, India |
Antwerp University Hospital, Edegem, Belgium |
AOU Città della Salute e della Scienza di Torino, Turin, Italy |
Arthur Bloom Haemophilia centre, Cardiff, United Kingdom |
Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy |
Azienda Ospedaliero Universitaria di Parma, Parma, Italy |
BC Children’s Hospital, Vancouver, Canada |
Beijing Children’s Hospital, Beijing, China |
Belarusian Centre for Paediatric Oncology and Haematology, Minsk, Belarus |
Bern University Hospital, Bern, Switzerland |
Bloodworks Northwest, Seattle, United States |
Calvary Mater Hospital/John Hunter Children’s Hospital, Newcastle, Australia |
Center for Bleeding and Clotting, Minneapolis, United States |
Center for Hemorrhagic and Thrombotic Diseases, University Hospital of Udine, Udine, Italy |
Center for Inherited Blood Disorders, Orange County, United States |
Centre de traitement des Hémophiles Eaubonne-Montmorency, Montmorency, France |
Centre de traitement des Hémophiles Hôpital, Mignot, France |
Centre Hospitalier Le Mans, Le Mans, France |
Centro Asistencial Regional de Hemoterapia (CARDHE), Bahia Blanca, Argentina |
Centro de Hemoterapia e Hematologia do Espirito Santo, Victoria, Brazil |
Centro Emofilia di Padova, Padova, Italy |
Centro Emofilia e Trombosi, Bari, Italy |
Centro Hospitalar de Lisboa Central, Lisbon, Portugal |
Centro Médico Imbanaco, Cali, Colombia |
Centro. Nacional de Hemofilia, Caracas, Venezuela |
CHEO Research Institute, Ottawa, Canada |
Children’s Hospital Colorado Anschutz Medical Campus, Aurora, United States |
Children’s Hospital of Michigan, Detroit, United States |
Children’s Hospital, Boston, United States |
Children’s Hospital, Los Angeles, United States |
Children’s Medical University Hospital, Riga, Latvia |
Children’s of Minnesota, Minneapolis, United States |
CHR de la Citadelle, Liège, Belgium |
Christchurch Hemophilia Treatment Centre, Christchurch, New Zealand |
CHRU de Besançon, Besançon, France |
CHU Caen, Caen, France |
CHU de Rouen, Rouen, France |
CHU Sainte Justine, Montreal, Canada |
CHU, University Hospital of Nancy, Nancy, France |
Clinique Vasculaire et Coagulation, Angers, France |
Complejo Asistencial Dr. Sótero del Río, Santiago, Chile |
Complejo Hospitalario de Navarra, Pamplona, Spain |
Congenital Coagulopathies Unit, Balearic Islands, Spain |
CTH-Cordoba, Cordoba, Argentina |
Dr. von Haunersches Kinderspital, Munich, Germany |
Ege University Hospital, Izmir, Turkey |
Emory University, Atlanta, United States |
Erasmus MC, Sophia Children’s Hospital, Rotterdam, Netherlands |
Exeter and Barnstaple Haemophilia Centre, Barnstaple, United Kingdom |
Farwaniya General Hospital, Al Farwaniyah, Kuwait |
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy |
Fondazione Policlinico universitario “Agostino Gemelli”, Rome, Italy |
Foothills Medical Centre, Calgary, Canada |
Fundación de Hemofilia de Salta, Salta, Argentina |
Fundacion de la Hemofilia Rosario, Rosario, Argentina |
Fundacion de la Hemofilia, Buenos Aires, Argentina |
Gent University Hospital, Gent, Belgium |
Gulf States Hemophilia, Houston, United States |
Haematology and Haemophilia Centre Catelfranco Veneto, Catelfranco Veneto, Italy |
Haemophilia Centre Copenhagen, Copenhagen, Denmark |
Haemophilia Centre of Perugia, Perugia, Italy |
Haemophilia Comprehensive Care Ljubljana, Ljubljana, Slovenia |
Hamilton Health Sciences, Hamilton, Canada |
Hämophilie-Zentrum Rhein Main GmbH, Frankfurt, Germany |
Heim Pál Gyermekkórház, Budapest, Hungary |
Helsinki University Hospital, Helsinki, Finland |
Hematologia y oncologia del oriente SAS, Bogota, Colombia |
Hematology and Oncology Department, CHU Nord, St. Etienne, France |
Hemocentro Unicamp, São Paulo, Brazil |
Hemofiliecentrum, UZ Leuven, Leuven, Belgium |
Hemophilia Center of Western New York, Buffalo, United States |
Hemophilia Center of Western Pennsylvania, Pittsburgh, United States |
Hemophilia Comprehensive Care Team, Jakarta, Indonesia |
Hemophilia Treatment Center of Central PA, Hershey, United States |
Hemostasis and Thrombosis Center of Nevada, Las Vegas, United States |
Hemostasis and Thrombosis Center Rhode Island, Rhode Island, United States |
Hôpital de l’Enfant-Jésus, Quebec City, Canada |
Hôpital Trousseau, CHRU de Tours, Tours, France |
Hôpital Universitaire des Enfants Reine Fabiola, Huderf, Belgium |
Hôpitaux Universitaires de Genève, Geneva, Switzerland |
Hospital Alvaro Cunqueiro, Vigo, Spain |
Hospital Clinico Universitario de Santiago, Santiago, Spain |
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain |
Hospital de Santa Maria, Lisbon, Portugal |
Hospital General Universitario de Alicante, Alicante, Spain |
Hospital Humberto Notti, Mendoza, Argentina |
Hospital Miguel Servet, Zaragoza, Spain |
Hospital Posadas, Buenos Aires, Argentina |
Hospital Regional Universitario de Málaga, Málaga, Spain |
Hospital Roberto del Río, Santiago, Chile |
Hospital Sant Joan de Déu, Barcelona, Spain |
Hospital Teresa Herrera Materno Infantil, Coruna, Spain |
Hospital Universitario Dr José Eleuterio Gonzalez, Monterrey, Mexico |
Hospital Universitario La Paz, Madrid, Spain |
Hospital Universitario Virgen de la Arrixaca, Murcia, Spain |
Hospital University and Politechnic La Fe, Valencia, Spain |
Hospital Vall d’Hebron, Barcelona, Spain |
Hospital Virgen de las Nieves, Granada, Spain |
Hull and East Yorkshire Hospitals NHS Trust, Hull, United Kingdom |
Indiana Hemophilia and Thrombosis Center, Indianapolis, United States |
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Science, Tianjin, China |
Instituto Guatemalteco de Seguridad Social, Guatemala City, Guatemala |
Intergral Solutions SD S.A.S, Bogota, Colombia |
IPS Especializada, Bogota, Colombia |
IWK Health Centre, Halifax, Canada |
Johns Hopkins All Children’s Hospital, St. Petersburg, United States |
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan |
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia |
Kingston General Hospital, Kingston, Canada |
Klinik für Kinder- und JugendmedizinUniversitätsklinikum Jena, Jena, Germany |
Korea Hemophilia Foundation Seoul Clinic, Seoul, South Korea |
Kuopio University Hospital, Kuopio, Finland |
Kyung Hee University Hospital at Gangdong, Seoul, South Korea |
Laiko General Hospital of Athens, Athens, Greece |
L’hemostase de Strasbourg, Strasbourg, France |
London Health Sciences Center, London, Canada |
Luzerner Kantonsspital, Lucerne, Switzerland |
Manitoba Health Sciences Centre, Winnipeg, Canada |
Massachusetts General Hospital, Boston, United States |
Maxima Medisch Centrum, Veldhoven, Netherlands |
Mohács Hospital, Mohács, Hungary |
Montreal Children’s Hospital, Montreal, Canada |
Nagoya University Hospital, Nagoya, Japan |
Nanfang Hospital, Guangzhou, China |
National Haemophilia Center Budapest, Budapest, Hungary |
Nationwide Children’s Hospital, Columbus, United States |
Nemours Children’s Specialty Care, Jacksonville, United States |
North Dakota Hemostasis and Thrombosis Treatment Center, Fargo, United States |
North Estonia Medical Center, Tallinn, Estonia |
Northern Alberta Bleeding and Rare Blood Disorders Clinic - Kaye Edmonton Clinic, Edmonton, Canada |
Northwest Ohio Hemophilia Treatment Center, Toledo, United States |
Ogikubo Hospital, Tokyo, Japan |
Oklahoma Center for Bleeding and Clotting Disorders, Oklahoma City, United States |
ONCOORIENTE SAS, Villavicencio, Colombia |
Oregon Health and Science University, Portland, United States |
Orthopaedic Hemophilia Treatment Center, Los Angeles, United States |
Ospedale S. Bortolo, Vicenza, Italy |
Oulu University Hospital, Oulu, Finland |
Palmetto Health Richland, Columbia, United States |
Pediatric Hemophilia Center of Turin, Italy |
Peking Union Medical College Hospital, Beijing, China |
Phoenix Children’s Hospital, Phoenix, Unites States |
Policlinico di Palermo, Palermo, Italy |
Policlinico Umberto I - “Sapienza” Università di Roma, Rome, Italy |
Pontificia Universidad Católica de Chile, Santiago, Chile |
Rady Children’s Hospital, San Diego, United States |
Riley Children’s Health, Indianapolis, United States |
Royal Adelaide Hospital, Adelaide, Australia |
Royal Brisbane and Women’s Hospital, Brisbane, Australia |
Royal Free Hospital, London, United Kingdom |
Royal London, London, United Kingdom |
Ruan Rehacer IPS, Bogota, Colombia |
Rush University Medical Center, Chicago, United States |
Sahlgrenska University Hospital, Gothenburg, Sweden |
Saskatchewan Bleeding Disorders Program, Saskatoon, Canada |
Sheffield Children’s Hospital, Sheffield, United Kingdom |
SickKids Hospital, Toronto, Canada |
Skåne University Hospital, Malmö, Sweden |
South Texas Hemophilia Treatment Center, San Antonio, United States |
St. George’s University Hospital, London, United Kingdom |
St. Joseph’s Hospital - Center for Bleeding and Clotting Disorders, Tampa, United States |
St. Jude Affiliate Clinic at NH Hemby Children’s Hospital, Charlotte, United States |
St. Jude Children’s Research Hospital, Memphis, United States |
St. Michael’s Hospital, Toronto, Canada |
St. Paul’s Hospital, Vancouver, Canada |
St-Luc University Hospital, Brussels, Belgium |
Stollery Children’s Hospital, Edmonton, Canada |
Taichung Veterans General Hospital, Taichung, Taiwan |
Taipei Medical University Hospital Hemophilia Center, Taipei, Taiwan |
Tampere University Hospital, Tampere, Finland |
The Alfred Hospital, Melbourne, Australia |
The Bleeding and Clotting Disorders Institute, Peoria, United States |
The Children’s Hospital at Montefiore, New York, United States |
The Children’s Hospital of Philadelphia, Philadelphia, United States |
The Children’s Hospital, Zhengjiang University School of Medicine, Hangzhou, China |
The Maine Hemophilia and Thrombosis Center, Scarborough, United States |
The Royal Children’s Hospital, Melbourne, Australia |
The Women’s and Childrens Hospital, Adelaide, Australia |
Turku University Hospital, Turku, Finland |
U.O. Pediatria Generale e Specialistica “B. Trambusti”, Bari, Italy |
UHHS Cleveland. University Hospitals Health System, Cleveland, United States |
Universitaets - Kinderklinik Wien, Vienna, Austria |
Universitätsklinikum Bonn, Bonn, Germany |
University Children’s Hospital Berne, Berne, Switzerland |
University Children’s Hospital Zurich, Zurich, Switzerland |
University Hospital Bristol, Bristol, United Kingdom |
University Hospital Brno, Brno, Czech Republic |
University Hospital Coventry and Warwickshire, Coventry, United Kingdom |
University Hospital Magdeburg, Magdeburg, Germany |
University Hospital Southampton, Southampton, United Kingdom |
University Hospitals of Leicester, Leicester, United Kingdom |
University Medical Center Utrecht, Utrecht, Netherlands |
University Medical Centre Ljubljana, Ljubljana, Slovenia |
University of California San Francisco Pediatric Hemophilia Treatment Center, San Francisco, United States |
University of Debrecen, Debrecen, Hungary |
University of Florida Hemophilia Treatment Cente, Gainsville, United States |
University of Helsinki and Children’s Hospital, Helsinki, Finland |
University of Iowa Children’s Hospital, Iowa City, United States |
University of Kentucky Hemophilia Treatment Center, Lexington, United States |
University of Louisville, Louisville, United States |
University of Miami Hemophilia Treatment Center, Miami, United States |
University of North Carolina, Chapel Hill, United States |
University of Szeged, Szeged, Hungary |
University of Virginia Health System, Charlottesville, United States |
University of Wisconsin Comprehensive Program for Bleeding Disorders, Madison, United States |
Valley Children’s Healthcare, Madera, United States |
Vanderbilt University Medical Center, Nashville, United States |
Vivantes Clinic in Friedrichshain, Berlin, Germany |
Wake Forest University, Winston-Salem, United States |
Weill Cornell Medical College, New York, United States |
Zurich University Hospital, Zurich, Switzerland |
Rights and permissions
About this article
Cite this article
McEneny-King, A., Chelle, P., Foster, G. et al. Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization. J Pharmacokinet Pharmacodyn 46, 411–426 (2019). https://doi.org/10.1007/s10928-019-09634-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-019-09634-7